Novartis Designs “Arogya Parivar” Initiative To Reach India’s Rural Centers
This article was originally published in The Pink Sheet Daily
Executive Summary
“Healthy Family” takes 24 Sandoz generics into tier-three and tier-four markets as part of a health education, clinic program.
You may also be interested in...
GSK To Take Second Shot At The Rural Indian Market; Considering Customized Strategy
MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.